<DOC>
	<DOC>NCT00508742</DOC>
	<brief_summary>This study is designed to assess the impact of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) on nasopharyngeal colonization with Streptococcus pneumoniae in healthy infants.</brief_summary>
	<brief_title>Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy infants aged 2 months (4298 days) at time of enrolment. Available for the entire study period and whose parent/legal guardian can be reached by telephone. Previous vaccination with licensed or investigational pneumococcal vaccine. A previous anaphylactic reaction to any vaccine or vaccinerelated component. Contraindication to vaccination with a pneumococcal conjugate vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>98 Days</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Nasopharyngeal Colonization</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Healthy Infants</keyword>
	<keyword>Vaccines</keyword>
	<keyword>Pneumococcal Conjugate Vaccine</keyword>
</DOC>